---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-26-000013"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:48:49.626577+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks FY2025 revenue up 39% to $106M, net loss down 34%; $250M royalty-backed note from Royalty Pharma

## Summary
- FY2025 revenue $106.0M (+39% YoY); net loss $81.1M vs $122.7M in 2024.
- Cash & securities $270.6M as of Dec 31; $62.5M used for share repurchases at avg $24.22/share.
- Entered $250M non-recourse royalty-backed note with Royalty Pharma; 70% of Ziihera royalty unencumbered.
- Partner Jazz expects Ziihera sBLA submission in 1Q 2026, potential launch in 2H 2026; up to $440M milestones eligible.
- 2026 adjusted gross opex guided ~20% lower than 2025 adjusted opex of $170.5M, excluding acquisitions.

## SEC filing metadata
- accession: 0001937653-26-000013
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/0001937653-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/zyme-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-26-000013
- JSON: https://secwatch.observer/filing/0001937653-26-000013.json
- Plain text: https://secwatch.observer/filing/0001937653-26-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.